Top-line data from the study showed that people treated with amycretin experienced a weight loss of 9.7% for the 1.25 mg dose over 20 weeks ... AZN & Daiichi’s Enhertu for Expanded Breast ...

CAMBRIDGE, MA—Mersana Therapeutics, Inc. (NASDAQ:MRSN) recently reported that Ashish Mandelia, the company's Vice President and Chief Accounting Officer, executed a sale of common stock.

In this article, I will share six reasons why I believe AstraZeneca stock is undervalued ... continued strong demand for Lynparza, Calquence, Enhertu, reflecting their superior efficacy relative ...

On January 16, Mohan sold 5,939 shares of common stock at an average price of $0.58 ... On the clinical front, Mersana's XMT-1660 has reached a dose escalation of 115 mg/m² in Phase I trials ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Enhertu reduced the risk of disease progression ... Price Action: AstraZeneca stock is up 0.09% at $70.14 during the premarket session at last check Tuesday.

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...